medigraphic.com
Organo Oficial de la Sociedad Mexicana de Urología

2020, Number 3

<< Back Next >>

Rev Mex Urol 2020; 80 (3)

2020: Mexican urology in times of COVID-19. A literature review and COVID-19 pandemic update for urologists

Chein-Vázquez MF, Tarot-Chocooj CP, Reyes-Vallejo LA, Rodriguez-Covarrubias F, Campos-Salcedo JG

Language: Spanish
References: 27
Page: 1-14
PDF size: 292.54 Kb.


ABSTRACT

Background: Coronaviruses are pathogens that affect animals and humans, causing neurologic, respiratory, intestinal, and hepatic diseases. Six coronaviruses are known to cause disease in humans. The current pandemic began in the Chinese city of Wuhan, in the province of Hubei, where the first case of pneumonia was reported on December 12, 2019. In February of 2020, the World Health Organization named the virus COVID-19 and the International Committee on Taxonomy of Viruses named it SARS-CoV-2. By April 30, 2020, more than 3 000 000 cases were confirmed worldwide, affecting 185 countries, with over 200 000 deaths and approximately 420 000 recoveries.
Relevance: A literature review was carried out to provide urologists with the current status of the disease in Mexico, the pathophysiology of the infectious disease caused by SARS-CoV-2, and the latest updates on the different treatment options for COVID-19.
Conclusions: Because we form part of the healthcare system, it is necessary for urologists to have the latest information on this disease of worldwide importance, given that we are involved with the management of COVID-19 patients at certain hospital centers.


REFERENCES

  1. Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020 Mar;579(7798):270–3. doi: https://doi.org/10.1038/s41586-020- 2012-7

  2. Jin Y, Yang H, Ji W, Wu W, Chen S, Zhang W, et al. Virology, Epidemiology, Pathogenesis, and Control of COVID-19. Viruses. 2020 Mar 27;12(4):372. doi: https://doi. org/10.3390%2Fv12040372

  3. Perlman S. Another Decade, Another Coronavirus. N Engl J Med. 2020 Feb 20;382(8):760–2. doi: https://doi. org/10.1056%2Fnejme2001126

  4. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020;109:102433. doi: https://doi.org/10.1016/j. jaut.2020.102433

  5. OMS. Alocución de apertura del Director General de la OMS en la rueda de prensa sobre la COVID-19 celebrada el 11 de marzo de 2020. 2020. [accessed 11 May 2020] Available from: https://www.who.int/es/dg/speeches/detail/ who-director-general-s-opening-remarks-at-themedia- briefing-on-covid-19---11-march-2020

  6. Leung K, Wu JT, Liu D, Leung GM. Firstwave COVID-19 transmissibility and severity in China outside Hubei after control measures, and second-wave scenario planning: a modelling impact assessment. The Lancet. 2020 Apr;395(10233):1382–93. doi: http://dx.doi. org/10.1016/s0140-6736(20)30746-7

  7. Johns Hopkins Coronavirus Resource Center. COVID-19 Map. 2020. [accessed 11 May 2020] Available from: https://coronavirus.jhu.edu/ map.html

  8. Sistema Nacional de Vigilancia Epidemiológica, Gobierno de México. Mapa interactivo COVID-19 en México. gob.mx. 2020. [accessed 11 May 2020] Available from: https:// coronavirus.gob.mx/

  9. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020 Feb 20;382(8):727–33. doi: https://doi. org/10.1056%2Fnejmoa2001017

  10. Guo Y-R, Cao Q-D, Hong Z-S, Tan Y-Y, Chen S-D, Jin H-J, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status. Military Medical Research. 2020 Mar 13;7(1):11. doi: https://doi.org/10.1186/ s40779-020-00240-0

  11. Song C, Wang Y, Li W, Hu B, Chen G, Xia P, et al. Detection of 2019 novel coronavirus in semen and testicular biopsy specimen of COVID-19 patients. medRxiv. 2020 Apr 10;2020.03.31.20042333. doi: https://doi. org/10.1101/2020.03.31.20042333

  12. Organization WH. Laboratory testing for coronavirus disease 2019 (COVID-19) in suspected human cases: interim guidance, 2 March 2020. 2020; [accessed 11 May 2020] Available from: https://apps.who.int/iris/ handle/10665/331329

  13. Long Q-X, Liu B-Z, Deng H-J, Wu G-C, Deng K, Chen Y-K, et al. Antibody responses to SARSCoV- 2 in patients with COVID-19. Nat Med. 2020 Apr 29; doi: https://doi.org/10.1038/ s41591-020-0897-1

  14. Qu J, Wu C, Li X, Zhang G, Jiang Z, Li X, et al. Profile of IgG and IgM antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020 Apr 27; doi: https://doi.org/10.1093/cid/ciaa489

  15. Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, et al. Detection of SARS-CoV-2 in Different Types of Clinical Specimens. JAMA. 2020 Mar 11; [accessed 11 May 2020] Available from: https://jamanetwork.com/journals/jama/ fullarticle/2762997

  16. Lu H. Drug treatment options for the 2019- new coronavirus (2019-nCoV). BioScience Trends. 2020;14(1):69–71. doi: https://doi. org/10.5582/bst.2020.01020

  17. Prevention C for DC and. Interim clinical guidance for management of patients with confirmed coronavirus disease (COVID-19). URL disponible en https://www cdc gov/ coronavirus/2019-ncov/hcp/clinical-guidancemanagement- patients html# Sepsis. 2020;

  18. Organization WH. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected: interim guidance, 13 March 2020. World Health Organization; 2020.

  19. Smith T, Bushek J, Prosser T. COVID-19 Drug Therapy – Potential Options. 2020;12.

  20. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020 Apr 13; [accessed 11 May 2020] Available from: https://jamanetwork. com/journals/jama/fullarticle/2764727

  21. Llau JV, Ferrandis R, Sierra P, Hidalgo F, Cassinello C, Gómez-Luque A. Propuesta de recomendaciones de manejo de fármacos anticoagulantes y antiagregantes en los pacientes graves con infección por COVID-19. Sociedad Española de Anestesiología, Reanimación y Terapéutica del Dolor; 2020 Mar. Available from: https://www.sedar. es/images/site/NOTICIAS/coronavirus/ RECOMENDACIONES_hemostasia-COVIDfinal. pdf

  22. Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost. 2020 May 6;jth.14830. doi: https:// doi.org/10.1111/jth.14830

  23. Smith T, Bushek J, LeClaire A, Prosser T. COVID-19 Drug Therapy. Clinical Drug Information, Clinical Solutions. 2020;

  24. Wang J, Hajizadeh N, Moore EE, McIntyre RC, Moore PK, Veress LA, et al. Tissue Plasminogen Activator (tPA) Treatment for COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS): A Case Series. J Thromb Haemost. 2020 Apr 8; doi: https://doi. org/10.1111/jth.14828

  25. Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020;18(5):1023–6. doi: https://doi. org/10.1111/jth.14810

  26. Curtis N. BCG Vaccination to Protect Healthcare Workers Against COVID-19 - Full Text View - ClinicalTrials.gov. 2020. [accessed 11 May 2020] Available from: https://clinicaltrials.gov/ ct2/show/NCT04327206

  27. Reducing Health Care Workers Absenteeism in Covid-19 Pandemic Through BCG Vaccine - Full Text View - ClinicalTrials.gov. 2020. [accessed 11 May 2020] Available from: https:// clinicaltrials.gov/ct2/show/NCT04328441




2020     |     www.medigraphic.com